Poster presentation at 2023 AACR meeting

HaemaLogiX is pleased to announce that the anti-KMA CAR-T cell preclinical data demonstrating proof of concept has been completed and was the subject of a poster presentation at the 2023 Annual Meeting of the American Association for Cancer Research (AACR), held 14-19 April in Orange County.

HaemaLogiX’s Chief Scientific Officer, Dr Rosanne Dunn,  presented the poster at the AACR meeting.

We’re developing the anti-KMA CAR-T to treat kappa-type multiple myeloma. The preclinical development of anti-KMA CAR-T was conducted as a research collaboration project with the Centre of Excellence in Cellular Immunotherapy at the Peter MacCallum Cancer Centre.

The poster presentation can be found here.

The Abstract publication on the AACR website can be found here.